16.12.2014Genomic Health -Breast cancer test obtains positive reimbursement in SwitzerlandYou are hereNewsGenomic Health -Breast cancer test obtains positive reimbursement in Switzerland
Genomic Health announced that starting on January 1, 2015, the Oncotype DX breast cancer test will be covered in Switzerland through the mandatory health insurance system. This means that patients with early-stage, hormone receptor-positive, HER2 negative, invasive breast cancer with up to three positive lymph nodes will have access to the Oncotype DX breast cancer test to help determine whether they are likely to benefit from chemotherapy in addition to hormonal therapy.
ORTHOMANUFACTURE 201820.06.2018European event for implants and surgical Instruments manufacturing technologies. Orthopaedics, traumatology, spine,...
Interview du nouveau Président de BioAlps par l'AgefiPhilippe D. Monnier a parlé avec Claude Clément, nouveau Président de BioAlps, de son nouveau rôle et sa vision...
BiiONR&D Services and Technology Platforms, Other
BiiON is constantly working on making easier the monitoring of a production's environment and equipments, providing a solution multi-brand, multi-site, multi-source: Mirrhia.
R&D Services and Technology Platforms, Technology Platforms (BioSystems, BioChips, BioMems)
With over 20 years of business experience in aseptic areas, Mirrhia is the quality assurance of the production.
BiiON offers a wide range of ICT services & Process Automation solutions:
Environmental Monitoring System (EMS)
Alarm & Data Management (AMS)
Quality & Regulatory Services
Manufacturing Execution System